EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Combination treatment with medium dose THC and CBD had no therapeutic effect in a transgenic mouse model for Alzheimer's disease but affected other domains including anxiety-related behaviours and object recognition memory

Beate Aumer, Rossana Rosa Porto, Madilyn Coles, Nina Ulmer, Georgia Watt, Heike Kielstein, Tim Karl

Pharmacology Biochemistry and Behavior · 2025

DOI: 10.1016/j.pbb.2025.174101 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology Biochemistry and Behavior, 2025. Verfasst von Beate Aumer und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Western Sydney University, NSW, 2560, Australia; Institute of Anatomy and Cell Biology, Martin Luther University Halle-Wittenberg…. Hauptthemen laut MEDLINE: Dronabinol, Cannabidiol, Alzheimer Disease, Anxiety. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fight MND, Western Sydney University, German Academic Exchange Service.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is a neurodegenerative disease that effects memory and behaviour. The phytocannabinoid cannabidiol (CBD) has been found to reverse impairments of recognition as well as spatial memory deficits of AD transgenic mice but had only limited effects on disease-relevant brain pathologies. Recent evidence suggests that combining CBD with other cannabinoids including delta-9-tetrahydrocannabinol (THC) may lead to improved therapeutic outcomes. Thus, this study evaluated the chronic effects of combined treatment with 3 mg/kg THC and 20 mg/kg CBD on 14.5-month-old APPSwe/PS1ΔE9 (APP/PS1) transgenic females and control littermates. Mice were treated with THCxCBD or vehicle (VEH) daily via intraperitoneal injections for 3 weeks before behavioural testing commenced. AD-relevant behavioural domains were analysed utilising Elevated Plus Maze (EPM), open field (OF), novel object recognition test (NORT), social interaction (SI), Y-maze (YM), and prepulse inhibition test (PPI). APP/PS1 females showed an anxiety-like phenotype and object recognition deficits that remained unchanged by cannabinoid treatment. Interestingly, some effects of THCxCBD appeared genotype-dependent with cannabinoid treatment causing an anxiogenic EPM response in APP/PS1 mice but having an anxiolytic-like effect in WT females. Moreover, THCxCBD administration disrupted the novel object preference of control females. Noteworthy, THCxCBD significantly decreased different fat depots and bodyweight of all mice across genotype. No other differences between genotypes or treatment groups were detected. In conclusion, the particular cannabinoid combination strategy utilised had no prominent therapeutic-like effect in 14.5-month-old APP/PS1 females.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DronabinolCannabidiolAlzheimer DiseaseAnxietyRecognition, PsychologyAnimalsMice, TransgenicFemaleMiceDisease Models, AnimalBehavior, AnimalMaze LearningDrug Therapy, Combination

Stichwörter der Autor:innen

Alzheimer's disease therapyBehaviourCannabidiol (CBD)Transgenic female APP(Swe)/PS1ΔE9 micedelta-9-tetrahydrocannabinol (THC)

Substanzen

DronabinolCannabidiol

Autor:innen und Institutionen

  • School of Medicine, Western Sydney University, NSW, 2560, Australia; Institute of Anatomy and Cell Biology, Martin Luther University Halle-Wittenberg, Große Steinstraße 52, 06108, Halle, Germany.
  • School of Medicine, Western Sydney University, NSW, 2560, Australia.
  • School of Medicine, Western Sydney University, NSW, 2560, Australia; Technical University of Munich, Arcisstraße 21, 80333, Munich, Germany.
  • Institute of Anatomy and Cell Biology, Martin Luther University Halle-Wittenberg, Große Steinstraße 52, 06108, Halle, Germany.
  • School of Medicine, Western Sydney University, NSW, 2560, Australia. Electronic address: t.karl@westernsydney.edu.au.

Förderung

  • Fight MND
  • Western Sydney University
  • German Academic Exchange Service
  • Bundesministerium für Forschung, Technologie und Raumfahrt
  • New South Wales Ministry of Health
  • NSW Health

Zitieren

APA

Aumer, B., Rosa Porto, R., Coles, M., Ulmer, N., Watt, G., Kielstein, H., & Karl, T. (2025). Combination treatment with medium dose THC and CBD had no therapeutic effect in a transgenic mouse model for Alzheimer's disease but affected other domains including anxiety-related behaviours and object recognition memory. Pharmacology Biochemistry and Behavior. https://doi.org/10.1016/j.pbb.2025.174101

Vancouver

Aumer B, Rosa Porto R, Coles M, Ulmer N, Watt G, Kielstein H, et al. Combination treatment with medium dose THC and CBD had no therapeutic effect in a transgenic mouse model for Alzheimer's disease but affected other domains including anxiety-related behaviours and object recognition memory. Pharmacology Biochemistry and Behavior. 2025. doi:10.1016/j.pbb.2025.174101

BibTeX
@article{Aumer2025,
  author = {Aumer, Beate and Rosa Porto, Rossana and Coles, Madilyn and Ulmer, Nina and Watt, Georgia and Kielstein, Heike and Karl, Tim},
  title = {Combination treatment with medium dose THC and CBD had no therapeutic effect in a transgenic mouse model for Alzheimer's disease but affected other domains including anxiety-related behaviours and object recognition memory},
  journal = {Pharmacology Biochemistry and Behavior},
  year = {2025},
  doi = {10.1016/j.pbb.2025.174101}
}
Kostenlos starten →